BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
BMI1
DOI:
10.1002/ijc.25522
Publication Date:
2010-06-21T17:40:34Z
AUTHORS (6)
ABSTRACT
The BMI1 oncogene promotes prostate cancer (PC) progression. High B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) expression predicts poor prognosis in PC patients. Recent evidence suggests that may also play a role docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1-related chemoresistance have not been investigated. For this purpose, was silenced 2 cell lines (LNCaP DU 145). Cell proliferation apoptosis after treatment were measured. Guanine oxidation assessed by in-cell western. Global gene analysis performed on cells. Oncomine database used to compare vitro data with samples. silencing had no effect but significantly enhanced docetaxel-induced antitumor activity. Gene demonstrated downregulates set antioxidant genes. Docetaxel increased guanine oxidation, whereas the N-acetyl cysteine rescued death. Examination datasets revealed positive correlation expression. BMI1-controlled genes predictive In conclusion, enhances response, thereby allowing survival docetaxel-based chemotherapy. are overexpressed aggressive should be tested as predictors chemotherapy failure.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (37)
CITATIONS (66)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....